The Vanderbilt Institute for Surgery and Engineering (VISE) team of Robert Webster III, PhD, and Duke Herrell, MD, have received a $2.2 million grant from the National Institutes of Health to develop a new surgical robot for endoscopic transurethral prostatectomy.
A recent study provides clinicians genomic guidance for surveillance of targeted therapy resistance in patients with EGFR-mutant non-small cell lung cancer — and more importantly — another drug option when resistance occurs.
A report by researchers at Vanderbilt University Medical Center has shattered conventional wisdom about how cells, including cancer cells, shed DNA into the bloodstream: they don’t do it by packaging the genetic material in tiny vesicles called exosomes.
The 20th Annual Scientific Retreat will be held Wednesday, May 1, 8:30 a.m. to 3 p.m., at the Vanderbilt University Student Life Center. Registration is free, but attendees should register by April 26. The topic of the retreat is “Signal Transduction in Cancer Initiation, Progression and Treatment.”
Finding gives boost to fighting cancer through cell metabolism
Uncontrolled activation of RAS causes approximately a third of all tumors and helps cancerous cells evade anti-cancer drugs. Vanderbilt researchers have identified small molecules that target this pathway and further defined how these small molecule compounds work.
Vanderbilt investigators report that a medicine currently being tested as a chemoprevention agent for multiple types of cancer can also act directly reduce the virulence of Helicobacter pylori, the primary cause of gastric cancer.
A precise understanding of how the enzyme topoisomerase II cuts DNA could lead to better anti-cancer therapies.
Vanderbilt-Ingram Cancer Center Ambassadors surpassed the $1 million mark with the awarding of the group’s latest research grants.
A recent study found that renal cell carcinoma cells with mutations in an enzyme-encoding gene, SETD2, were sensitive to a drug that inhibits the enzyme PI3K-beta.